Skip to main content
OSCOTECInc. logo

OSCOTECInc. — Investor Relations & Filings

Ticker · 039200 ISIN · KR7039200001 KO Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country KR South Korea
Listing KO 039200

About OSCOTECInc.

https://oscotec.com/

Oscotec Inc. is a clinical-stage drug discovery and development company focused on translating scientific research into innovative medicines for clinically unmet needs. The company's development pipeline targets various diseases, with a primary focus on immunology, oncology, and neurodegenerative disorders. Key therapeutic areas include rheumatoid arthritis, immune thrombocytopenia, non-small cell lung cancer, acute myeloid leukemia, and Alzheimer's disease. Oscotec specializes in developing novel kinase inhibitors, such as Spleen Tyrosine Kinase (SYK) inhibitors, to address these conditions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (SKIO703의 약물 제형 변경을 위한 임상 1상 IND 승인)
Regulatory Filings Classification · 95% confidence The document is a corporate disclosure announcing the approval of a clinical trial plan (IND) by the Korean MFDS, containing details of the trial design, dates, and related risk warnings. It is not a financial report (10-K, IR, ER), not a management or board change (MANG), not an earnings release (ER), nor any other specific category such as M&A, dividends, or share issues. It is a routine regulatory announcement required under Korean securities rules. Hence it falls under the fallback category Regulatory Filings (RNS).
2026-05-22 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 98% confidence The document is the Korean “주식등의 대량보유상황보고서(약식)” (Report on the status of large shareholdings) filed by Tiger Asset Management, detailing acquisition and disposition of OscoTech shares and reporting a crossing of the 5% ownership threshold. This matches a Major Shareholding Notification. There is no indication of an AGM, earnings release, management change, or other category. Therefore, it is classified as MRQ.
2026-05-22 Korean
기업설명회(IR)개최
Investor Presentation Classification · 85% confidence The document is an announcement of a planned Investor Relations (IR) presentation (기업설명회) with date, time, location, audience, agenda, and sponsor details. This aligns with an Investor Presentation event notification rather than a financial report or regulatory filing. Therefore, it should be classified as Investor Presentation (IP).
2026-05-14 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제 29기 1분기)” covering the period January 1 to March 31, 2026, and contains comprehensive financial tables, management discussion, business overview, and detailed quarterly financial statements. This aligns with the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-14 Korean
투자판단관련주요경영사항 (유한양행의 얀센바이오테크 기술이전 마일스톤 분배)
Regulatory Filings Classification · 75% confidence The document is a standalone Korean regulatory disclosure (“투자판단 관련 주요경영사항”) detailing a milestone payment from a license agreement. It is not an investor presentation, earnings report, or share issue, nor does it contain full financial statements. It is a generic material event announcement, so it falls into the fallback “Regulatory Filings” category, code RNS.
2026-05-14 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming Investor Relations (IR) event, specifically a corporate presentation scheduled for May 12, 2026. It includes details such as date, time, location, target audience, purpose, and contact information. The document does not contain actual financial statements or detailed financial analysis but rather information about the event and when the presentation materials will be posted. This fits the definition of an Investor Presentation (IP) as it is a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual materials will be posted later. The document length is short and it is not a report publication announcement since it describes the event itself, not just the release of a report. Therefore, the correct classification is Investor Presentation (IP).
2026-05-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.